Endocrine Abstracts

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...

Introduction: This non-interventional study assesses real-life use and potential predictive parameters for lanreotide (LAN) in pts with either acromegaly (ACRO) or NET over a period of 24 months. We present a pre-specified interim analysis after first 6 months of therapy.Methods: The primary objective is to evaluate the long term treatment response under LAN and to correlate it with early changes of biochemical markers. The planned sample size is 152 (76...

Introduction: Data demonstrating antiproliferative effects of somatostatin analogs (SSAs) in enteropancreatic NETs are limited; only one prospective trial so far has shown this for patients with midgut tumors and low hepatic tumor load (HTL). CLARINET is the first large phase 3, randomized, placebo-controlled trial evaluating such effects for the SSA lanreotide in patients with non-functioning enteropancreatic NETs.Methods: Patients who had well/moderate...